• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Anticoagulation in CKD: Trials and Tribulations.

作者信息

Mohsen Mai, Zhang Tracy, Battistella Marisa

机构信息

Department of Pharmacy, University Health Network, Toronto, Ontario, Canada.

Leslie Dan Faculty of Pharmacy, University of Toronto, Ontario, Canada.

出版信息

Kidney Med. 2023 Jun 8;5(7):100686. doi: 10.1016/j.xkme.2023.100686. eCollection 2023 Jul.

DOI:10.1016/j.xkme.2023.100686
PMID:37427294
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10329163/
Abstract
摘要

相似文献

1
Anticoagulation in CKD: Trials and Tribulations.慢性肾脏病中的抗凝治疗：试验与困境
Kidney Med. 2023 Jun 8;5(7):100686. doi: 10.1016/j.xkme.2023.100686. eCollection 2023 Jul.
2
Atrial fibrillation in CKD: balancing the risks and benefits of anticoagulation.慢性肾脏病中的心房颤动：权衡抗凝治疗的风险与获益。
Am J Kidney Dis. 2013 Sep;62(3):615-32. doi: 10.1053/j.ajkd.2013.02.381. Epub 2013 Jun 5.
3
Anticoagulation in chronic kidney disease: from guidelines to clinical practice.慢性肾脏病的抗凝治疗：从指南到临床实践。
Clin Cardiol. 2019 Aug;42(8):774-782. doi: 10.1002/clc.23196. Epub 2019 May 28.
4
Clinical benefits and risks of anticoagulation therapy according to the degree of chronic kidney disease in patients with atrial fibrillation.根据房颤患者慢性肾脏病的严重程度评估抗凝治疗的临床获益和风险。
BMC Cardiovasc Disord. 2023 Apr 25;23(1):209. doi: 10.1186/s12872-023-03236-5.
5
Anticoagulation in CKD and ESRD.慢性肾脏病和终末期肾病患者的抗凝治疗。
J Nephrol. 2019 Oct;32(5):719-731. doi: 10.1007/s40620-019-00592-4. Epub 2019 Jan 28.
6
Oral Anticoagulation in Patients With Advanced Chronic Kidney Disease and Atrial Fibrillation: Beyond Anticoagulation.慢性肾脏病晚期合并心房颤动患者的口服抗凝治疗：超越抗凝。
Mayo Clin Proc. 2023 May;98(5):750-770. doi: 10.1016/j.mayocp.2023.01.007. Epub 2023 Apr 5.
7
Atrial fibrillation and chronic kidney disease: struggling through thick and thin.心房颤动与慢性肾脏病：艰难前行。
Nephrol Dial Transplant. 2017 Jul 1;32(7):1079-1084. doi: 10.1093/ndt/gfw378.
8
Anticoagulation in atrial fibrillation: the trials and tribulations of keeping within therapeutic range.心房颤动的抗凝治疗：维持在治疗范围内的试验与困难
Curr Med Res Opin. 2008 May;24(5):1455-8. doi: 10.1185/030079908x301875. Epub 2008 Apr 9.
9
Effect of chronic kidney disease on warfarin management in a pharmacist-managed anticoagulation clinic.慢性肾脏病对抗凝门诊药师管理华法林治疗的影响。
J Manag Care Pharm. 2011 Sep;17(7):523-30. doi: 10.18553/jmcp.2011.17.7.523.
10
Relation of Renal Dysfunction to Quality of Anticoagulation Control in Patients with Atrial Fibrillation: The FANTASIIA Registry.肾功能不全与心房颤动患者抗凝控制质量的关系：FANTASIIA 登记研究。
Thromb Haemost. 2018 Feb;118(2):279-287. doi: 10.1160/TH17-06-0416. Epub 2018 Jan 29.

引用本文的文献

1
Anticoagulation Strategies for Atrial Fibrillation in CKD Stage G5 and Dialysis Patients: An Updated Scoping Review.慢性肾脏病5期及透析患者心房颤动的抗凝策略：最新综述
Rev Cardiovasc Med. 2025 Mar 5;26(3):26736. doi: 10.31083/RCM26736. eCollection 2025 Mar.
2
Hallmarks for Thrombotic and Hemorrhagic Risks in Chronic Kidney Disease Patients.慢性肾脏病患者血栓形成和出血风险的特征。
Int J Mol Sci. 2024 Aug 9;25(16):8705. doi: 10.3390/ijms25168705.

本文引用的文献

1
Safety and Effectiveness of Rivaroxaban Versus Warfarin Across GFR Levels in Atrial Fibrillation: A Population-Based Study in Australia and Canada.利伐沙班与华法林在不同肾小球滤过率水平的心房颤动患者中的安全性和有效性：一项基于澳大利亚和加拿大人群的研究。
Kidney Med. 2023 May 16;5(7):100675. doi: 10.1016/j.xkme.2023.100675. eCollection 2023 Jul.
2
Association of Chronic Kidney Disease With Atrial Fibrillation in the General Adult Population: A Nationwide Population-Based Study.慢性肾脏病与普通成年人群心房颤动的相关性：一项全国范围内基于人群的研究。
J Am Heart Assoc. 2023 Apr 18;12(8):e028496. doi: 10.1161/JAHA.122.028496. Epub 2023 Apr 17.
3
Reversal agents for current and forthcoming direct oral anticoagulants.目前和即将推出的直接口服抗凝剂的逆转剂。
Eur Heart J. 2023 May 21;44(20):1795-1806. doi: 10.1093/eurheartj/ehad123.
4
Cardiorenal Outcomes Among Patients With Atrial Fibrillation Treated With Oral Anticoagulants.口服抗凝剂治疗的心房颤动患者的心脏肾脏结局
Am J Kidney Dis. 2023 Mar;81(3):307-317.e1. doi: 10.1053/j.ajkd.2022.07.017. Epub 2022 Oct 5.
5
Drug-Drug Interactions of Direct Oral Anticoagulants (DOACs): From Pharmacological to Clinical Practice.直接口服抗凝剂（DOACs）的药物相互作用：从药理学到临床实践
Pharmaceutics. 2022 May 24;14(6):1120. doi: 10.3390/pharmaceutics14061120.
6
Safety and Efficacy of DOACs in Patients with Advanced and End-Stage Renal Disease.直接口服抗凝药物在晚期和终末期肾病患者中的安全性和疗效。
Int J Environ Res Public Health. 2022 Jan 27;19(3):1436. doi: 10.3390/ijerph19031436.
7
The 2020 Canadian Cardiovascular Society/Canadian Heart Rhythm Society Comprehensive Guidelines for the Management of Atrial Fibrillation.2020 年加拿大心血管学会/加拿大心律学会心房颤动管理综合指南。
Can J Cardiol. 2020 Dec;36(12):1847-1948. doi: 10.1016/j.cjca.2020.09.001. Epub 2020 Oct 22.
8
Position paper on the safety/efficacy profile of direct oral anticoagulants in patients with chronic kidney disease. Consensus document from the SIN, FCSA and SISET.关于直接口服抗凝剂在慢性肾脏病患者中的安全性/疗效特征的立场文件。来自 SIN、FCSA 和 SISET 的共识文件。
Blood Transfus. 2020 Nov;18(6):478-485. doi: 10.2450/2020.0156-20. Epub 2020 Aug 6.
9
2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC.2020年欧洲心脏病学会（ESC）与欧洲心胸外科学会（EACTS）合作制定的心房颤动诊断和管理指南：欧洲心脏病学会（ESC）心房颤动诊断和管理特别工作组，由ESC欧洲心律协会（EHRA）特别贡献制定。
Eur Heart J. 2021 Feb 1;42(5):373-498. doi: 10.1093/eurheartj/ehaa612.
10
Direct Oral Anticoagulant Use: A Practical Guide to Common Clinical Challenges.直接口服抗凝药物的应用：常见临床挑战的实用指南。
J Am Heart Assoc. 2020 Jul 7;9(13):e017559. doi: 10.1161/JAHA.120.017559. Epub 2020 Jun 15.